{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:01Z","timestamp":1761541021430,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1379,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Heart, Lung, and Blood Institute and the National Cancer Institute through National Institutes of Health","award":["U01-8L069294"],"award-info":[{"award-number":["U01-8L069294"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bbmt.2010.11.004","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T04:43:29Z","timestamp":1289450609000},"page":"1051-1057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response"],"prefix":"10.1016","volume":"17","author":[{"given":"Marcie R.","family":"Tomblyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Ewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginna G.","family":"Laport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.11.004_bib1","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.11.004_bib2","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib3","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib4","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib5","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.11.004_bib6","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.11.004_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.11.004_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib9","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbmt.2008.04.007","article-title":"Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma","volume":"14","author":"Kuruvilla","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib12","doi-asserted-by":"crossref","first-page":"150a","DOI":"10.1182\/blood.V110.11.486.486","article-title":"Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients with advanced idolent NHL and CLL: CALGB 109901","volume":"110","author":"Shea","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib13","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced-intensity conditioning HLA-identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pinana","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.11.004_bib14","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib15","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.11.004_bib17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/1740774508098326","article-title":"Use of biological assignment in hematopoietic stem cell transplantation clinical trials","volume":"5","author":"Logan","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.bbmt.2010.11.004_bib19","unstructured":"Blood and Marrow Transplantation Clinical Trials Network. Manual of procedures. 2010. Available at: https:\/\/web.emmes.com\/study\/bmt2\/MOP.html. Accessed Sept 20, 2010."},{"key":"10.1016\/j.bbmt.2010.11.004_bib20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI-Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.11.004_bib21","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.11.004_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib23","first-page":"825","article-title":"1994 Consensus Conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing-risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2010.11.004_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2010.11.004_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.11.004_bib27","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","article-title":"Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan","volume":"36","author":"Kusumi","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2008.02.014","article-title":"Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation","volume":"14","author":"Tomblyn","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.11.004_bib30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.11.004_bib31","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/sj.leu.2402302","article-title":"Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo\/immunotherapy for patients with high-risk non-Hodgkin\u2019s lymphoma","volume":"15","author":"Ladetto","year":"2001","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110005021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110005021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:39:04Z","timestamp":1761057544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110005021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1083879110005021"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.11.004","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}